Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Breast Cancer Female. 2. Age 20-65 years. 3. Invasive carcinoma confirmed by core biopsy. 4. Newly diagnosed breast cancer patients, without adjuvant therapy. 5. Imaging findings showed a single breast tumor with a maximum diameter of 3 cm, no distant metastasis, and no invasion of the skin and chest wall. 6. Systematic ultrasound is able to visualize lesions. 7. Surgical treatment was planned. 8. The functional level of major organs must meet the following requirements: 1. blood routine: neutrophil (ANC) ≥ 1.5 × 109/L; platelet count (PLT) ≥ 90 × 109/L; hemoglobin (Hb) ≥ 90 g/L; 2. blood biochemistry: total bilirubin (TBIL) ≤ upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN; 3. coagulation: international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. 4. Heart: left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography (ECHO) or multigated acquisition (MUGA). 5. Thyroid function: thyroid stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be investigated, and normal T3 and T4 levels can be included. 6. Urinalysis: urine protein < 2 +, if urine protein ≥ 2 +, 24-hour urine protein quantification must show protein ≤ 1 g. 9. Voluntarily participate in this study, sign informed consent, have good compliance and are willing to cooperate with follow-up  Tumor involving skin, ulceration, inflammatory breast cancer patients 2. Fatty breast cancer. 3. Tumors on the deep surface of areolar region 4. KPS score < 70, or ECOG score > 2 5. Patients with a history of concomitant collagen connective tissue disease, or any active autoimmune disease or autoimmune disease. 6. Prior radiotherapy or prior use of investigational drugs or other immunosuppressive agents 7. Heart, brain, lung, kidney and other vital organ failure, liver and kidney dysfunction; 8. Uncorrectable severe coagulopathy 9. Patient is pregnant or lactating 10. Poor glycemic control in diabetes 11. Patients with foreign body implantation around the tumor 12. Patients with severe scars on the skin of the treatment area (protruding from the skin surface, width ≥ 1 cm) 13. History of chronic immunosuppression, prior immunotherapy, recent vaccination (< 4 weeks) 14. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B indicates antigen positive and HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection of the analytical method). 15. Concurrent medical conditions that, in the judgment of the investigator, would jeopardize the subject's safety, could confound the study results, or affect the subject's completion of this study